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ABSTRACT 
A meta-analysis titled as “b1-adrenoceptor gene Arg389Gly polymorphism and 
essential hypertension risk in general population: a meta-analysis” was used as basis 
of our study. The meta-analysis was published in 2013 on Mol Biol Rep and included 
eight articles, published before June 2012. Also, we searched the PubMed database 
for other studies published after June 2012, but nothing else returned as result.  
Our goal was to assess the studies included in the above meta-analysis by using the 
STREGA Statement. Nine case-controls or cross-sectional studies were assessed for 
their conformity to the recommendations of the STREGA Statement. 
Finally, a qualitative overall analysis was performed.  The results indicated high 
degree of conformity to the STREGA Statement concerning to Hardy-Weinberg 
equilibrium, selection criteria of participants, statistical methods and reporting of 
software used, reporting of descriptive and outcome data, source and method 
genotyping of DNA and statement for replication. Less encouraging findings concern 
to population stratification and number of successful genotyping, On the contrary, 
low conformity was revealed for the genotyping errors, modelling haplotype 
variation and   control for relatedness.  
 
In conclusion, the Genetic Association Studies (GAS) for the variant ADRB1 
p.Arg389Gly in hypertension might be improved in reference to the STREGA 
Statement, for greater transparency and more reliability. 
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INTRODUCTION 
 
HYPERTENSION AND VARIANT ADRB1 p.Arg389Gly 
 
Hypertension is one of the most common chronic illnesses effecting more than one 
billion people worldwide and is one of the primary risk factors for coronary artery 
disease and myocardial infarction, heart failure, stroke and renal failure. By the year 
2025, the global prevalence of hypertension is projected to increase to 29.2% in 
adult population (Kearney et al., 2005). It is well established that reduction in blood 
pressure is associated with decreased cardiovascular morbidity and mortality 
(Lewington, Clarke, Qizilbash, Peto, & Collins, 2002). Despite the availability of 
several antihypertensive drugs which include thiazide diuretics, beta blockers, 
Angiotensin-Converting Enzyme (ACE) inhibitors, angiotensin receptor blockers (ARB) 
and calcium channel blockers, global estimates suggest that less than 35% of 
hypertensives are able to achieve their target systolic and diastolic blood pressure 
with these drugs (Thoenes et al., 2009). 
Essential hypertension (EH) is widely accepted as a multifactorial disorder caused by 
both genetic and environmental influences.  Genetic factors have been reported to 
take up 20–60 %. Consequently, hypertension susceptibility genes have been being 
under exploration, to identify the candidate determinants of the risk for 
hypertension. 
The adrenergic receptors (adrenoceptors) family genes have emerged as logical 
candidate genes for hypertension based on experimental evidence showing 
involvement of the SNS in hypertension and on positional cloning findings from 
genome -wide linkage studies. The adrenoceptors belong to the G-protein coupled 
receptors superfamily, which are integral membrane proteins with seven 
transmembrane helices, responsible for the signal transduction of a variety of 
extracellular signals. Neuronally released and circulating catecholamines bind to 
adrenoceptors to stimulate the intracellular signal transduction cascade and finally 
exert their biologic effect. The adrenoceptors family is sub-classified into α1-, α2- or 
β- adrenoceptors, although each of these classes has multiple subtypes so that a 
total of nine subtypes have been characterized: α1A-, α1B-, α1D-, α2A-, α2B-, α2C-, 
β1-, β2- and β3-adrenoceptors. Each of these adrenoceptors subtypes is coded by a 
separate gene (ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, 
ADRB2 and ADRB3, respectively) and has a different tissue distribution and function. 
Overall, 2250 genetic variants have been annotated to the adrenoceptors family 
(Kitsios & Zintzaras, 2010). 
 
The genetic candidate, that interests us, is the gene β1-adrenoceptor (ADRB1). The 
human β1-adrenoceptor (ADRB1) is a key cell surface signaling protein expressed in 
multiple organs and tissues including heart, kidney, brain and pineal gland, which 
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mediates the actions of catecholamines like epinephrine and norepinephrine in the 
sympathetic nervous system (SNS). The β1-adrenergic receptor (ADRB1) belongs to 
the family of guanine nucleotide binding regulatory protein coupled receptors 
(GPCRs). ADRB1 is expressed in the heart and mediates the physiological effects of 
catecholamines. The human β1-adrenergic receptor is encoded by an intronless gene 
with 45 aminoacids located on chromosome 10q24-262. Of the 73 polymorphisms of 
ADRB1 gene identified so far, 13 of these result in change of amino acid in the 
ADRB1 protein. 
Two nonsynonymous single nucleotide polymorphisms (SNP) have been identified in 
ADRB1: Arg389Gly, which causes a substitution of arginine by glycine at amino acid 
position 389 and Ser49Gly, which replaces serine with glycine at position 49. 
The following figure shows the structure of β1-Adrenoceptor single nucleotide 
polymorphisms. 
.
 
 
Figure 1:  b1-Adrenoceptor single nucleotide polymorphisms. 
AC      : adenylyl cyclase 
ATP    : adenosine triphosphate 
cAMP : cyclic adenosinemonophosphate 
GDP    :  guanosine diphosphate 
GTP     : guanosine triphosphate 
 
At the molecular level, the role of ADRB1 in EH has been extensively evaluated, with 
particular attention on Arg389Gly (rs1801253) single-nucleotide polymorphisms 
(SNP). However, the results of these genetic association studies(GAS) are 
controversialand inconclusive, possibly due to methodological limitations, including 
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inadequate samplesize, patient selection, ethnicity of the populations studied and 
lack of adjustments forconfounders. 
 
THE   STREGA STATEMENT  
The rapidly evolving evidence on genetic associations is crucial to integrating human 
genomics into the practice of medicine and public health. Genetic factors are likely 
to affect the occurrence of numerous common diseases, and therefore identifying 
and characterizing the associated risk (or protection) will be important in improving 
the understanding of etiology and potentially for developing interventions based on 
genetic information.Assessment of the strengths and weaknesses of this evidence, 
and hence the ability to synthesize it, has been limited by inadequate reporting of 
results. The number of publications on the associations between genes and diseases 
has increased tremendously; with more than 34000 published articles, the annual 
number has more than doubled between 2001 and 2008. Articles on genetic 
associations have been published in about 1500 journals and in several languages. 
The quality of reporting genetic association studies needs to be improved. Lack  of 
transparency and incomplete reporting have raised concerns in a range of health 
research fields and poor reporting has been associated with biased estimates of 
effects in clinical intervention studies. At first, the epidemiology community has 
developed the Strengthening the Reporting of Observational studies in Epidemiology 
(STROBE) Statement for cross-sectional, case-control and cohort studies. The 
recommendations of the STROBE Statement have a strong foundation because they 
are based on empirical evidence on the reporting of observational studies and they 
involved extensive consultations in the epidemiologic research community. Given 
the relevance of general epidemiologic principles for genetic association studiesand 
the fact that genes may operate in complex pathways with gene-environment and 
gene-gene interactions STREGA recommendations as an extension of the STROBE 
Statement were necessary. So, the epidemiology community has developed The 
STrengthening the REporting of Genetic Association studies (STREGA), with main 
goal to propose and justify a set of guiding principles for reporting results of genetic 
association studies. 
The STrengthening the REporting of Genetic Association studies (STREGA) initiative 
builds on the Strengthening the Reporting of Observational Studies in Epidemiology 
(STROBE) Statement and provides additions to 12 of the 22 items on the STROBE 
checklist. Five main areas of special interest that are specific to, or especially 
relevant in, genetic association studies are identified: genotyping errors, population 
stratification, modelling haplotype variation, HWE and replication. Each of these 
areas with the corresponding STREGA recommendations, is followed by an 
explanation for their necessity. Complementary information on these areas and the 
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rationale for additional STREGA recommendations relating to selection of 
participants, choice of genes and variants selected, treatment effects in studying 
quantitative traits, statistical methods, relatedness, reporting of descriptive and 
outcome data and issues of data volume, are given. 
The additions concern: population stratification, genotyping errors, modelling 
haplotype variation, Hardy-Weinberg equilibrium, replication, selection of 
participants, rationale for choice of genes and variants, treatment effects in studying 
quantitative traits, statistical methods, relatedness, reporting of descriptive and 
outcome data and the volume of data issues that are important to consider in 
genetic association studies. 
The STREGA recommendations do not prescribe or dictate how a genetic association 
study should be designed but seek to enhance the transparency of its reporting, 
regardless of choices made during design, conduct, or analysis. 
Below, the five main areas of special interest of STREGA are described: 
1. Genotyping Errors 
Recommendation for reporting of methods (Table 1, item 8(b)): Describe laboratory 
methods, including source and storage of DNA, genotyping methods and platforms 
(including the allele calling algorithm used and its version), error rates and call rates. 
State the laboratory/center where genotyping was done. Describe comparability of 
laboratory methods if there is more than one group. Specify whether genotypes 
were assigned using all of the data from the study simultaneously or in smaller 
batches. 
 Recommendation for reporting of results (Table 1, item 13(a)): Report numbers of 
individuals in whom genotyping was attempted and numbers of individuals in whom 
genotyping was successful. 
Genotyping errors can occur as a result of effects of the DNA sequence flanking the 
marker of interest, poor quality or quantity of the DNA extracted from biological 
samples, biochemical artefacts, poor equipment precision or equipment failure, or 
human error in sample handling, conduct of the array or handling the data obtained 
from the array. A commentary published in 2005 on the possible causes and 
consequences of genotyping errors observed that an increasing number of 
researchers were aware of the problem, but that the effects of such errors had 
largely been neglected.The magnitude of genotyping errors has been reported to 
vary between 0.5% and 30%. In high-throughput centers, an error rate of 0.5% per 
genotype has been observed for blind duplicates that were run on the same gel. This 
lower error rate reflects an explicit choice of markers for which genotyping rates 
have been found to be highly repeatable and whose individual polymerase chain 
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reactions (PCR) have been optimized. Non-differential genotyping errors, that is, 
those that do not differ systematically according to outcome status, will usually bias 
associations towards the null, just as for other non-differential errors. The most 
marked bias occurs when genotyping sensitivity is poor and genotype prevalence is 
high (>85%) or, as the corollary, when genotyping specificity is poor and genotype 
prevalence is low (<15%). When measurement of the environmental exposure has 
substantial error, genotyping errors of the order of 3% can lead to substantial 
underestimation of the magnitude of an interaction effect. When there are 
systematic differences in genotyping according to outcome status (differential error), 
bias in any direction may occur. Unblinded assessment may lead to differential 
misclassification. For genome-wide association studies of SNPs, differential 
misclassification between comparison groups (for example, cases and controls) can 
occur because of differences in DNA storage, collection or processing protocols, even 
when the genotyping itself meets the highest possible standards. In this situation, 
using samples blinded to comparison group to determine the parameters for allele 
calling could still lead to differential misclassification. To minimize such differential 
misclassification, it would be necessary to calibrate the software separately for each 
group. The recommendation is to specify whether genotypes were assigned using all 
of the data from the study simultaneously or in smaller batches. 
2. Population Stratification 
Recommendation for reporting of methods (Table 1, item 12(h): Describe any 
methods used to assess or address population stratification. 
Population stratification is the presence within a population of subgroups among 
which allele (or genotype; or haplotype) frequencies and disease risks differ. When 
the groups compared in the study differ in their proportions of the population 
subgroups, an association between the genotype and the disease being investigated 
may reflect the genotype being an indicator identifying a population subgroup rather 
than a causal variant. In this situation, population subgroup is a confounder because 
it is associated with both genotype frequency and disease risk. The potential 
implications of population stratification for the validity of genetic association studies 
have been debated. Modelling the possible effect is likely to be small in most 
situations. Meta-analyses of 43 gene-disease associations comprising 697 individual 
studies showed consistent associations across groups of different ethnic origin and 
thus provide evidence against a large effect of population stratification, hidden or 
otherwise. However, as studies of association and interaction typically address 
moderate or small effects and hence require large sample sizes, a small bias arising 
from population stratification may be important. Study design (case-family control 
studies) and statistical methods have been proposed to address population 
stratification, but so far few studies have used these suggestions. Most of the early 
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genome-wide association studies used family-based designs or such methods as 
genomic control and principal components analysis to control for stratification. 
These approaches are particularly appropriate for addressing bias when the 
identified genetic effects are very small (odds ratio <1.20), as has been the situation 
in many recent genome-wide association studies. In view of the debate about the 
potential implications of population stratification for the validity of genetic 
association studies, we recommend transparent reporting of the methods used, or 
stating that none was used to address this potential problem. This reporting will 
enable empirical evidence to accrue about the effects of population stratification 
and methods to address it. 
3. Modelling Haplotype Variation 
Recommendation for reporting of methods (Table 1, item 12(g):Describe any 
methods used for inferring genotypes or haplotypes. 
A haplotype is a combination of specific alleles at neighbouring genes that tends to 
be inherited together. There has been considerable interest in modelling haplotype 
variation within candidate genes. Typically, the number of haplotypes observed 
within a gene is much smaller than the theoretical number of all possible haplotypes. 
Motivation for utilizing haplotypes comes, in large part, from the fact that multiple 
SNPs may “tag” an untypical variant more effectively than a single typed variant. The 
subset of SNPs used in such an approach is called “haplotype tagging” SNPs. 
Implicitly, an aim ofhaplotype tagging is to reduce the number of SNPs that have to 
be genotyped, while maintaining statistical power to detect an association with the 
phenotype. Maps of human genetic variation are becoming more complete, and 
large scale genotypic analysis is becoming increasingly feasible. In consequence, it is 
possible that modelling haplotype variation will become more focused on rare causal 
variants, because these may not be included in the genotyping platforms 
4.  Hardy-Weinberg Equilibrium 
Recommendation for reporting of methods (Table 1, item 12(f)):State whether 
Hardy-Weinberg equilibrium was considered and, if so, how. 
Hardy-Weinberg equilibrium has become widely accepted as an underlying model in 
population genetics after Hardy and Weinberg proposed the concept that genotype 
frequencies at a genetic locus are stable within one generation of random mating; 
the assumption of HWE is equivalent to the independence of two alleles at a locus. 
Views differ on whether testing for departure from HWE is a useful method to detect 
errors or peculiarities in the data set, and also the method of testing In particular, it 
has been suggested that deviation from HWE may be a sign of genotyping errors. 
Testing for departure from HWE has a role in detecting gross errors of genotyping in 
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large-scale genotyping projects such as identifying SNPs for which the clustering 
algorithms used to call genotypes have broken down. However, the statistical power 
to detect less important errors of genotyping by testing for departure from HWE is 
low and, in hypothetical data, the presence of HWE was generally not altered by the 
introduction of genotyping errors. Furthermore, the assumptions underlying HWE, 
including random mating, lack of selection according to genotype, and absence of 
mutation or gene flow, are rarely met in human. Moreover, exclusion of HWE-
violating studies may result in loss of the statistical significance of some postulated 
gene-disease associations and that adjustment for the magnitude of deviation from 
the model may also have the same consequence for some other gene-disease 
associations. Given the differing views about the value of testing for departure from 
HWE and about the test methodstransparent reporting of whether such testing was 
done and, if so, the method used, is important for allowing the empirical evidence to 
accrue. 
5. Replication 
Recommendation (Table 1, item 3): State if the study is the first report of a genetic 
association, a replication effort, or both. 
Articles that present and synthesize data from several studies in a single report are 
becoming more common. In particular, many genome-wide association analyses 
describe several different study populations, sometimes with different study designs 
and genotyping platforms, and in various stages of discovery and replication. When 
data from several studies are presented in a single original report, each of the 
constituent studies and the composite results should be fully described. For 
example, a discussion of sample size and the reason for arriving at that size would 
include clear differentiation between the initial group (those that were typed with 
the full set of SNPs) and those that were included in the replication phase only 
(typed with a reduced set of SNPs).Describing the methods and results in sufficient 
detail would require substantial space in print, but options for publishing additional 
information on the study online make this possible. 
The STREGA Statement has several strengths. First, it is based on existing guidance 
on reporting observational studies (STROBE). Second, it was developed from 
discussions of an interdisciplinary group that included epidemiologists, geneticists, 
statisticians, journal editors, and graduate students, thus reflecting a broad 
collaborative approach in terminology accessible to scientists from diverse 
disciplines. Finally, it explicitly describes the rationale for the decisions (Table 2) and 
has a clear plan for dissemination and evaluation. 
Adherence to the recommendations may make some manuscripts longer, and this 
may be seen as a drawback in an era of limited space in a print journal. However, the 
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ability to post information on the Web should alleviate this concern. The place in 
which supplementary information is presented can be decided by authors and 
editors of the individual journal. 
As basis of the aforementioned was used the article with the title:  “STrengthening 
the REporting of Genetic Association Studies (STREGA) – An Extension of the STROBE 
Statement”, that was published in 2009 by a team of significant scientists and 
researchers from various centers and countries. The workshop team consisted of  
Julian Little,  Julian P.T. Higgins, John P.A. Ioannidis David Moher, France Gagnon, 
Erik von Elm, Muin J. Khoury, Barbara Cohen, George Davey-Smith, Jeremy 
Grimshaw, Paul Scheet, Marta Gwinn, Robin E. Williamson, Guang Yong Zou, Kim 
Hutchings, Candice Y. Johnson, Valerie Tait, Miriam Wiens, Jean Golding, Cornelia 
van Duijn,  John McLaughlin, Andrew Paterson, George Wells, Isabel Fortier, 
Matthew Freedman, Maja Zecevic, Richard King, Claire Infante-Rivard,  Alex Stewart,  
Nick Birkett. 
The head of team was Julian Little,  Canada Research Chair in Human Genome 
Epidemiology, from Department of Epidemiology and Community Medicine 
University of Ottawa. 
In order to encourage dissemination of the STREGA Statement, the article has also 
been published by the Annals of Internal Medicine, European Journal of 
Epidemiology, European Journal of Clinical Investigation, Genetic Epidemiology, 
Human Genetics, Journal of Clinical Epidemiology as well as PLoS Medicine. The 
article has been placed in the public domain and can be freely reproduced, 
distributed, transmitted, modified, built upon, or otherwise used by anyone for any 
lawful purpose. 
The STREGA recommendations are available at www.strega-statement.org 
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METHODS 
 
Selection of studies 
A meta-analysis titled as “b1-adrenoceptor gene Arg389Gly polymorphism and 
essential hypertension risk in general population: a meta-analysis” was used as 
basis of our study. It was performed by Hao Wang, Jielin Liu, Kuo Liu, Ya Liu, 
Zuoguang Wang, Yuqing Lou, QiuliNiu, Wei Gu, Lijuan Wang, Mei Li, Xiaoling Zhu and 
Shaojun Wen and was published in 2013 on MolBiol Rep. In this meta-analysis, eight 
(8) articles, published before June 2012, were included. 
Also, we searched the PubMed database for other studies published after June 2012, 
but nothing else returned as result.  
Our goal was to assess the genetic association studies (GAS) included in the above 
meta-analysis by using the STREGA statement.  
The articles included in the meta-analysis were: 
1. Bengtsson K, Melander O, Orho-Melander M et al (2001) Polymorphismin the 
beta(1)-adrenergic receptor gene and hypertension. Circulation 104:187–190 
 
2. Filigheddu F, Reid JE, Troffa C et al (2004) Genetic polymorphismsof the beta-
adrenergic system: association with essentialhypertension and response to beta-
blockade. Pharmacogenomics J 4:154–160 
 
3. Nieminen T, Lehtimaki T, Laiho J et al (2006) Effects of polymorphisms in β1-
adrenoceptor and α-subunit of G protein on heart rate and blood pressure 
during exercise test. The FinnishCardiovascular Study. J Appl Physiol 100:507–
511 
 
4. Hu R, Zhao S, Niu G et al (2006) Association between essentialhypertension and 
polymorphisms of beta 1 adrenergic receptorgene G1165C (Gly389Arg) in 
Chinese Mongolian population.Neural Regen Res 1:226–229 
 
5. Borgel J, Schulz T, Bartels NK et al (2006) Modifying effects ofthe R389G beta1-
adrenoceptor polymorphism on resting heartrate and blood pressure in patients 
with obstructive sleep apnoea. Clin Sci (Lond) 110:117–123 
 
6. Gjesing AP, Andersen G, Albrechtsen A. et al (2007) Studies ofassociations 
between the Arg389Gly polymorphism of the beta1-adrenergic receptor gene 
(ADRB1) and hypertension and obesityin 7677 Danish white subjects. Diabet 
Med 24:392–397 
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7. Ramu P, Rajan S, Shewade DG et al (2009) Genetic variants ofbeta(1)-
adrenoceptor gene polymorphisms (Ser49Gly andArg389Gly) and essential 
hypertension in a south Indian Tamilpopulation. Clin Exp Pharmacol Physiol 
36:576–582 
 
8. Peng Y, Xue H, Luo L et al (2009) Polymorphisms of the beta1-adrenergic 
receptor gene are associated with essential hypertensionin Chinese. Clin Chem 
Lab Med 47:1227–1231 
 
Studies’ abstracts 
Initially, we present an abstract for each study. In all studies, hypertension 
wasdefined as: systolic blood pressure (SBP)>140 mmHg and/or diastolic blood 
pressure (DBP)>90 mmHg and/ortreatment with anti-hypertensive 
medicationaccording to World Health Organization (WHO) criteria, except the study 
by Bengtsson et al., in which the diagnostic standards were 160/90 mmHg for 
hypertensive patients and150/80 mmHg for normotensive controls, whichwere 
differentfrom other eligible studiesand likely this fact leads to heterogeneity, as the 
meta-analysis showed. Also, in one of the studies [6], both criteria for hypertension 
were used but there was no significant difference observed. Five of the articles were 
referring to Europeans (Italians, Scandinavians (2), Danish, Germans) and three of 
them in Asians (Mongolians, Chinese and Indians). 
In all studies, the protocols were approved by the local competent Ethical 
Committees, and all patients gave informed consent before the study initiation, as 
stipulated in the Declaration of Helsinki. 
 
1. Bengtsson K., Melander O., Orho-Melander M. et al (2001) Polymorphismin the 
beta(1)-adrenergic receptor gene and hypertension. Circulation 104:187–190 
 
Τhe present study is the first study that investigated whether the Arg389Gly 
polymorphism is associated with hypertension. It was conducted in Scandinavians. 
292 unrelated, nondiabetic, hypertensive patients and 265 unrelated healthy 
controlsubjects from Swedish were included in a case-control association study. 
Allele and genotype frequencies of the Arg389Gly polymorphisms were compared 
between hypertensive patients and normotensive control subjects.  
The Arg389 allele and the Arg389Arg genotype of the b1-adrenergic receptor gene 
were more common in patientswith hypertension than in controls.The age-, sex- and 
body mass index- adjusted odds ratio for hypertension in subjects homozygous for 
the Arg389 allele was 1.9 (95% confidence interval=1.3 to 2.7; P=0.0005) when 
compared with carriers of one or two copies of the Gly389 allele. SBP, DBP did not 
differ between carriers of the different Arg389Gly genotypes within the treated 
hypertension group or within the control group. 
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Also, for confirmation of results, a genotype-discordant sibling pair analysis was 
performed on 102 nondiabetic sibling pairs without antihypertensive medication. 
This genotype-discordant sibling pair analysis revealed that siblings homozygous for 
the Arg389 allele had significantly higher diastolic blood pressures DBP (P= 0.003) 
than siblings carrying one or two copies of the Gly389 allele.  
In conclusion, data suggest that individuals homozygous for the Arg389 allele of 
theb1-adrenergic receptor gene are at increased risk to develop hypertension. This is 
the single study, proposing positive association between the Arg389Arg genotype 
and hypertension. So, in the sensitivity analysis of the aforementioned meta-analysis 
this is a source of heterogeneity. 
 
2. Filigheddu F, Reid JE, Troffa C et al (2004) Genetic polymorphisms of the beta-
adrenergic system: association with essential hypertension and response to 
beta-blockade. Pharmacogenomics J 4:154–160 
 
The objectives of the present study were: 
 (1) to investigate the association of known polymorphisms of b1ARs(as R389Gb1AR) 
with EH in a cohort of genetically homogeneous EH patients and normotensive 
controls (case–control study)  
(2) to analyze the BP fall after 4 and 8 weeks of therapy with b-blockers according to 
genotype (pharmacogenetics study) in essential hypertensive patients never treated 
or untreated for at least 6 months. 
So, the study consists of two phases:a case-control study and a cohort 
pharmacogenetics study. 
In the case-control study, 526 cases (hypertensive patients) from the Hypertension 
and Cardiovascular Prevention Center, Sassari, Italy were recruited. Controls were 
192 normotensives white, unrelated North Sardinians. Due to laboratory failures, the 
final numbers of individuals in whom genotyping was successful were: 506 cases and 
175 controls. Cases and controls were not matched by age and BMI. So, stratification 
for gender and including these variables in the regression models were used to 
address this problem. 
In the pharmacogenetics study, 270 patients were treated with atenolol and the BP 
fall after 4 and 8 weeks of therapy was examined according to genotype.  
In conclusion, no association between ADRB1 Arg389Gly(R389Gb1AR)polymorphisms 
at the b1AR and EH was found, even considering gender specificity. Also no effect of 
the R389Gb1ARto the BP fall after 4 and 8 weeks of therapy with b-blockers was found 
in essential hypertensive patients never treated or untreated for at least 6 months. 
 
3. Nieminen T, Lehtimaki T, Laiho J et al (2006) Effects of polymorphisms in β1-
adrenoceptor and α-subunit of G proteinon heart rate and blood pressure 
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during exercise test. The FinnishCardiovascular Study. J ApplPhysiol 100:507–
511 
 
In this study, it was tested whether the Arg389Gly polymorphism of the β1-
adrenergic receptor gene ADRB1 modulates blood pressure responses during an 
exercise stress test. The study is a H-B study and the patients underwent exercise 
stress tests at the Tampere University Hospital between October 2001 and January 
2003. Finally, 890 patients with technically successful exercise tests and acquired 
genotypic samples were included in the study (563 men and 327 women). The study 
population was analyzed as a whole and divided based on gender.  
In all subjects, and in men and women separately, no statistically significant 
interaction was found for the ADRB1 Arg389Gly polymorphism in relation to SAP and  
DAP responses over the three study phases (rest, exercise, recovery) (RANOVA, 
P=0.10 for interaction in all analyses where age, BMI, and β-adrenergic antagonism 
were used as covariates). The Gly389 homozygotes had higher maximal SAP during 
exercise than those with at least one Arg389 allele; consequently, the change of SAP 
from the resting state to the maximal had the same pattern. Also, this polymorphism 
did not differentiate the blood pressure response during β-blocker treatment. 
 
4. Hu R, Zhao S, Niu G et al (2006) Association between essential hypertension 
and polymorphisms of beta 1 adrenergic receptorgene G1165C (Gly389Arg) in 
Chinese Mongolian population. Neural Regen Res 1:226–229 
 
The goal was to analyze the association between Arg3896Gly polymorphism and 
essential hypertension in Mongolian population, where the prevalence of 
hypertension, cerebrovascular diseases etc. are higher because of the influence of 
various factors (environmental, genetic, diet etc.).A cross-sectional study, with 239 
Mongolian participants, in three groups (122 essential hypertension patients,51 
subjects with simple high SBP and 117 subjects with normal BP) was carried out.  
The distribution of the genotypes and alleles of the ADRB1 Arg389Gly polymorphism 
have no obvious differences between normotensives, patients with essential 
hypertension and subjects with simple high SBP. So, in Mongolians, the ADRB1 
Arg389Gly polymorphism may be not a genetic mark of essential hypertension and 
simple high SBP. 
 
5. Borgel J, Schulz T, Bartels NK et al (2006) Modifying effects ofthe R389G beta1-
adrenoceptor polymorphism on resting heartrate and blood pressure in 
patients with obstructive sleep apnoea. Clin Sci (Lond) 110:117–123 
 
OSA (obstructive sleep apnoea) stimulates sympathetic nervous activity and elevates 
resting blood pressure. In the present study in a cohort of untreated OSA patients, 
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the resting BP during the daytime was correlated with AHI (apnoea/ hypopnea index) 
and compared with patients with different genotypes of the β1-adrenoreceptor 
R389G polymorphism. 309 untreated OSA patients were consecutively enrolled from 
1999–2001 in the sleep laboratory of the Marienhospital Herne (Ruhr University 
Bochum, Germany).  Arterial hypertension was diagnosed in 167 patients. So, the 
study was performed on 167 cases and 142 controls. Data showed that the R389R 
polymorphism is not associated with higher BP in untreated OSA patients. 
 Also, the impact of the the β1-adrenoreceptorR389G polymorphism on the decline 
of BP in a subgroup of 148 patients during a 6-month follow-up period under CPAP 
(continuous positive airway pressure) therapy was examined. In this follow-up 
cohort, the R389G polymorphism of the β1-adreno-ceptor appeared to have an 
impact on BP response to CPAP therapy. Carriers of the Gly389 (homozygotes and 
heterozygotes) exhibited a greater and significant decrease in DBP and SBP during 
CPAP therapy. However, differences in the BP-lowering effects of CPAP therapy 
between the genotype groups (R389R, R389G and G389G) did not reach statistical 
significance. 
 
6. Gjesing AP, Andersen G, Albrechtsen A et al (2007) Studies of associations 
between the Arg389Gly polymorphism of the beta1-adrenergic receptor gene 
(ADRB1) and hypertension and obesity in 7677 Danish white subjects. Diabet 
Med 24:392–397 
 
Case-control study and quantitative trait analyses were carried outin 7677 Danish 
Caucasians who were genotyped for the Arg389Gly variant. 
A case-control study exams the effect of Arg389Gly polymorphism on hypertension 
in Danish white subjects, in a relatively large-scale population.No association of the 
hypertension with allele frequencies (P = 0.3) or genotype distribution (P = 0.5) was 
found; however, in the quantitative trait analyses, individuals carrying the Gly allele 
had slightly but significantly lower diastolic and systolic  blood pressure as well as a 
lower mean arterial blood pressure.So, the ADRB1 Arg389Gly variant is most likely 
not to be a major contributor to the development of hypertension. However, it is 
possible that the Arg allele may contribute by causing a minor increase in systolic 
and diastolic blood pressure levels in a middle-aged white population, although the 
effect is not powerful enough to cause hypertension. 
7. Ramu P, Rajan S, Shewade DG et al (2009) Genetic variants of beta(1)-
adrenoceptor gene polymorphisms (Ser49Gly and Arg389Gly) and essential 
hypertension in a south Indian Tamil population. Clin Exp Pharmacol Physiol 
36:576–582 
The aim of the present study was to determine the association between β1-
adrenoceptor Arg389Glygene polymorphism and the susceptibility of individuals to 
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essential hypertension in a south Indian Tamil population. The participants were 438 
unrelated essential hypertensive patients(cases) and 444 healthy volunteers 
(controls). 
There were no significant differences in the genotypes and allele frequencies for 
Arg389Gly between hypertensive patients and controls. The adjusted ORs were 
1.1(95% CI: 0.8–1.7, P=0.5) for Arg/Gly  and 1.4 (95% CI:  0.8–2.3, P=0.2) for Gly/Gly. 
The results remained the same after sub-grouping the sample by gender. 
 
8. Peng Y, Xue H, Luo L et al (2009) Polymorphisms of the beta1-adrenergic 
receptor gene are associated with essential hypertensionin Chinese. Clin Chem 
Lab Med 47:1227–1231 
 
The goal of the present study was to investigate whether the functionally important 
Arg389Gly polymorphism of the ADRB1 gene was associated with hypertensionin 
Chinese.The hypothesis was tested in two independent case-control studies, one 
comprised 481 patients with hypertension and 529 control subjects, and the other 
study comprised 212 patients and 325 control subjects. The controls were recruited 
from age- and gender-matched healthy subjects from the same city. This is the first 
investigation to test the association between Arg389Gly or Ser49Gly ADRB1 
polymorphisms with hypertension in two independent populations. All participants 
were of the Han ethnic group. The present studies found that the Arg389Gly 
polymorphism of ADRB1 is associated with hypertension in Chinese. The first study 
showed that the Arg389Arg genotype of the ADRB1 gene was associated with risk of 
hypertension with odds ratio (OR) 1.77, (95% confidence interval (CI) 1.09–2.98; 
p=0.008), and the association was replicated in the second independent population 
(OR 1.65, 95% CI 1.07–2.89, ps0.01). Also, hypertensive patients with Arg389Arg 
variants had significantly increased DBP, in both studies. 
 
Data analysis 
We attempted to assess the studies mentioned on the above articles by using the 
STREGA statement. Each studywas analyzed according to the recommendations of 
the STREGA Statement, item by item. This analysis is presented in separate table for 
each study, presented in the Appendix.Some articles include more than one studies 
[1, 2, 5,8].Only the case-controls and cross-sectional studies included in the 
mentioned above meta-analysis, were assessed using the STREGA Statement. An 
overall assessment of conformity to the recommendations of the STREGA Statement 
was performed and presented.We attempted to assess studies, in conformity to the 
five main areas of special interest of STREGA. Particularly, we examined whether the 
studies satisfied the twelve additional items of STREGA, but also the items of 
STROBE. Finally, a qualitative analysis was conducted. 
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 RESULTS 
 
Nine studies included in the aforementioned articles were assessed by using the 
STREGA Statement. We attempted to assess studies, in conformity to the five main 
areas of special interest of STREGA. Particularly, we examined whether the studies 
satisfied the twelve additional items of STREGA, but also the items of STROBE, as 
basis. 
 
In most of the studies,laboratory methods, including source, extraction and storage 
of DNA, genotyping methods and platforms (including the allele calling algorithm 
used and its version) were described. On the contrary, no information for storage of 
DNA was given. Also, error rates and call rates of genotyping are not given except in 
one study [6]. In the study [2] the genotyping tests were duplicated, for excluding 
genomic errors and in the study [3] it was reported that negative and positive 
controls (known genotypes) and random duplicates were used as quality control. 
 
The numbers of individuals in whom genotyping was attempted and numbers of 
individuals in whom genotyping was successful were reported in studies [2, 3, 6, 7]. 
Numbers of participants for each genotype category were reported in all studies. 
 
The observed genotype frequencies in all studies, where population’sgenetic profile 
was documented, obeyed Hardy-Weinberg equilibrium (HWE). Besides, one of the 
inclusion criteria of the meta-analysis was genotype distribution among control 
populations must be in Hardy–Weinberg equilibrium.However, the genetic profile of 
the β1-ADRB has not yet been documented for any Indian population; so, in the 
relevant study [7] no statement for HWE existed. 
 
Software version used for the statistical analysis was stated in eight from those nine 
studies (89%). Only in one [5] of them, it was not stated and so deviation from this 
requirement was observed in this study. SPSS-in various editions- was used as 
software for the statistical analysis in six studies (78%), Intercooled Stata 7.0for 
Windows in one [2] (11%) and also NCSS 6.0.21i n one [1] (11%). The two last 
programs were used in the oldest studies [1, 2]. 
 
In most studies, the statement if the study is the first report of a genetic association, 
a replication effort or both was given. In cases, where no statement was expressed 
[5], the kind of the study was inferred. 
No information for potential sources of bias and bias resulting from 
pharmacotherapy and addressing them was given in most studies, except studies 
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[2,3]. 
Population stratification was excluded in studies [2, 3, 7, 8a, 8b] by the same ethnic 
origin and the homogeneity of population, or by using statistical methods. In the rest 
studies, none was used to address this potential problem. 
All studies, simply, reported unrelated participants but no method to address 
relatedness among subjects was presented. 
In three studies [4, 8a, 8b] no information for funding was given. Likely, it is 
interesting to be mentioned that all these studies refer to Asians (Chinese and 
Mongolians). So, 33% of the studies were not in conformity with that crucial for 
transparency requirement 
The findings of the assessment by the STREGA Statement are presented in the Table, 
below. 
Table: Findings of the assessment by the STREGA Statement 
STREGA recommendations Number 
of studies 
in conformity 
% 
of studies 
in conformity 
Comments 
Replication  7 78  [1,3,5,6, 8a, 8b] 
Selection criteria  9 100 All  
Genotyping 
Source  
Storage 
Genotyping Method/ platforms  
Error and Call rate 
 
8 
1 
8 
2 
 
89 
11 
89 
22 
 
All except [6] 
[2] 
All except [6] 
 [2,6] 
Potential sources of bias 1 11  [3] 
Potential bias resulting from 
pharmacotherapy 
2 22 [2,3] 
Effects of treatment 3 33 [2, 3, 5] 
Software version  used / 
settings chosen 
8 
9 
89 
100 
All except [5] 
Hardy-Weinberg equilibrium 8 89 All except [7] 
Inferring genotypes or 
haplotypes 
1 11 [7] 
Population stratification 5 55 [2, 3, 7, 8a, 8b] 
Control risk of false positive 
findings 
2 22 [2,6] 
Control of Relatedness among 
subjects 
0 0 None 
Number of successful 
genotyping 
4 44 [2, 3, 6,7] 
Information by genotype 8 89 All except [4] 
Outcomes or numbers for each 
genotype category 
9 100 All 
Detailed results elsewhere 2 22 [1,2] 
Funding 6 67 [1,2,3,5,6,7] 
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CONCLUSION 
 
The assessment of Genetic Association Studies for the variant ADRB1 p. Arg389Gly in 
hypertension indicated both positive and negative findings concerning to conformity 
to the STREGA Statement.The degree of conformity varied from item to item of the 
STREGA table, still in the same area (i.e.genotyping). 
 
High conformity (>75%) was observed for Hardy-Weinberg equilibrium, selection 
criteria of participants, statistical methods and reporting of software programs used, 
reporting of descriptive and outcome data (as outcomes for each genotype category, 
information by genotype), source and method genotyping of DNA and statement for 
replication or first effort. 
Medium degree of conformity (40-75%) appeared in population stratification and 
reporting of number of successful genotyping,  
On the other hand, low conformity (<40%) was revealed for the error rates and call 
rates of genotyping, the storage of DNA, the  effects in studying quantitative traits, 
modelling haplotype variation and control for relatedness among subjects. 
 
In conclusion, further improvement of GAS for the variant ADRB1 p. Arg389Gly in 
hypertension must be done, in reference to the STREGA recommendations. This is 
more necessary due to controversial results of several studies. This improvement will 
lead to greater transparency and more reliability. 
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ABBREVIATIONS 
 
ADRB1   :β1-Adrenergic Receptor 
AHI         : Apnoea/ Hypopnea Index 
BMI       : Body Mass Indes 
DAP      : Diastolic Arterial Pressure 
DBP       : Diastolic Blood Pressure 
EH         : Essential Hypertension 
GAS       :Genetic Association Studies 
MABP   : Mean Arterial Blood Pressure 
OSA       : Obstructive Sleep Apnoea 
SAP      : Systolic Arterial Pressure 
SBP      : Systolic Blood Pressure 
SNP      : Single Nucleotide Polymorphism 
STREGA: STrengthening the REporting of Genetic Association Studies 
STROBE : Strengthening the Reporting of Observational Studies in Epidemiology  
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TABLE 1: ASSESSMENT   OF 1st STUDY 
Item Item 
number 
Description Conformity 
with STREGA 
Title  
 
1 Polymorphism in the β1-Adrenergic 
Receptor Geneand Hypertension 
 
 
Introduction 
Background 
rationale 
2 BThe Arg389 variant of theb1-adrenergic 
receptor gene mediates a higher 
isoproterenol-stimulated adenylate 
cactivity than the Gly389 variant in vitro.  
 
Objectives 3 The aim of the present study was to 
investigate whether the functionally 
important Arg389Gly polymorphism of 
the b1-adrenergic receptor gene was 
associated with hypertension in a case-
control study. For confirmation of 
results, an additional independent 
sibling-pair study was performed. 
 
First attemption 
 
 
 
 
 
 
 
 
 
YES 
Methods 
Study design 4 Consists of two studies: 
1st study: a case-control study.  
It is the first study which examines the 
association between Arg389Gly and 
hypertension. 
 
For confirmation of results, an additional 
independent sibling-pair study was 
performed. 
2nd study: Sibling-Pair Study 
 
The local ethics committee approved the 
study, and written informed consent 
was obtained from all the participants 
 
 
YES 
 
 
 
 
 
 
 
 
 
Setting 5 All study subjects were from southern 
Sweden and participated in either the 
Skaraborg hypertension project (n5353) 
or in a family study (n5204) 
No dates 
determined 
Participants 6 1st  study:  case-control study.   
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Cases: 292 unrelated no diabetic 
hypertensive patients 
Selection criteria: 
(1) age at diagnosis of hypertension ≤60 
years  
(2) presence of chronic antihypertensive 
treatment 
(3) absence of diabetes mellitus. 
Controls: 265 unrelated healthy subjects 
Selection criteria: 
(1) age at the time of the study ≥40 
years 
(2) SBP≥150 mm Hg and DBP≥80 mm Hg 
(3) no personal history of elevated blood 
pressure or diabetes mellitus 
(4) no antihypertensive medication use 
(5) no family history of hypertension in 
first-degree relatives 
 
2nd study: Sibling-Pair Study  
491 siblings without antihypertensive 
medication were ascertained from 118 
families comprising 189 sibships from 
the Botnia study in Finland. Altogether, 
455 sibling-pair combinations were 
identified. (note: one sibling can appear 
in more than one sibling-pair) 
 
 
YES 
Variables 7 BP as:   
SBP(systolic),  DBP(diastolic) 
 Diagnostic Criteria: 140/90 mmHg 
 
As confounders:  
Age, Sex and BMI 
 
Genotype  
Data sources 
measurement 
8 1st  study:  case-control study.  
Blood pressure was measured in the 
supine position with a sphygmoma-
nometer after 5 minutes of rest 
 
Total genomic DNA was extracted from 
whole blood by standard methods. 
Arg389Gly polymorphism in the b1-
adrenergic receptor gene was 
genotyped by polymerase chainreaction 
and restriction fragment length 
polymorphism methods, as described 
elsewhere 
NO 
 
No 
information 
for storage of 
DNA, 
call rates, 
error rates. 
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References 
given for 
more details. 
Bias 9 The selection of the control subjects.  
All patients were on antihypertensive 
medication.- 
 
 
2nd study: Sibling-Pair Study 
The genotype-discordant sibling analysis 
is very powerful because siblings often 
share lifestyle factors influencing blood 
pressure and the risk for hypertension, 
such as diet, exercise habits, and 
socioeconomic status  
YES 
Study size 10 1st  study: Case-control study 
Cases: 292 Controls:265 
 
Quantitative 
Variables 
11 --------------------------------------------  
Statistical 
methods 
 
12 
 
 
 
 
Analyses were performed using NCSS 
6.0.21 (Statistical Solutions, Ltd). 
 
1st  study: Case-control study 
Continuous variables are presented as 
means6SD.  
Differences in proportions were tested 
by the x2 test 
Differences between means were tested 
by t test, ANOVA, or Kruskal-Wallis test, 
where appropriate.  
Multiple logistic regression was 
performed with hypertension as the 
dependent variable and age, BMI, sex, 
and codon 389 genotype (Gly389Gly and 
Arg389Gly versus Arg389Arg) as 
independent variables.  
A 2-sided P=0.05 was considered 
statistically significant. 
YES 
  
No data missing.  
  
No sensitivity analysis was conducted.  
All genotype distributions adhered to 
the Hardy-Weinberg equilibrium. 
YES 
No method to infer genotypes or 
haplotypes 
NO 
No method to address population 
stratification 
NO 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 12:46:38 EET - 137.108.70.7
No method to control risk of false 
positive findings 
NO 
No method to address relatedness 
among subjects 
NO 
Results 
Participants 
 
13 Case-Control Study: 
Cases: 292  
Controls: 265  
 
 
No changes in number of participants  
Descriptive data 
 
14 Information by genotype is given YES 
Outcome data 15 Number in each genotype category is 
reported 
YES 
Main results 
 
16 1st  study: Case-control study 
The Arg389 allele and the Arg389Arg 
genotype of the b1-adrenergic receptor 
gene were more common in patients 
with hypertension than in controls . 
The age-, sex-, and BMI-adjusted odds 
ratio for treated hypertension in 
subjects homozygous for the Arg389-
allele was 1.9 (95% CI: 1.3 to 2.7; 
P=0.0005) when compared with carriers 
of 1 or 2 Gly389 alleles.  
SBP, DBP did not differ between carriers 
of the different Arg389Gly genotypes 
within the treated hypertension group 
or within the control group.  
 
Other analyses 
 
17 2nd study: Sibling-Pair Study 
In the 102 sibling-pairs discordant for 
the Arg389Gly polymorphism, the 
siblings homozygous for the Arg389 
allele had a significantly higher DBP 
(P=0.003) and heart rate (P=0.02) than 
carriers of 1 or 2 Gly389 alleles, but 
there was no difference in SBP. Age and 
BMI were similar between siblings 
 
Discussion 
Key results 18 The Arg389Arg genotype of the b1-
adrenergic receptor gene confers an 
increased risk of developing 
hypertension. 
 
Limitations 19 A weakness of the case-control design is 
the selection of the control subjects. In 
addition, all patients were on 
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antihypertensive medication.  
 
Interpretation 20 In vitro studies have shown that the 
Arg389 variant of the b1-adrenergic 
receptor gene mediates an increased 
responseto agonist stimulation 
compared with the Gly389 variant, 
suggesting that the Arg389Gly 
polymorphism is of functional 
importance. The increased activity of the 
Arg389 variant of the b1-adrenergic 
receptor in vivo could be expected to 
lead to a higher cardiac output and 
could therefore explain our association 
between the Arg389 allele and 
hypertension. 
 
Generalizability 21 ------------------------------------------  
Other Information 
Funding 22 The research was funded by the Swedish 
Heart Lung Foundation; the Swedish 
Medical Research Council; the National 
Public Health Institute; the Skaraborg 
Institute; the Skaraborg County Council; 
the West Region County; the Region 
Skane; the Faculty of Medicine at Lund 
University; the PåhlssonFoundation, 
Malmö University Hospital; the 
ErnholdLundström Research 
Foundation; the Crafoord Foundations; 
and the NEPI Foundation (The Swedish 
Network of Pharmacoepidemiology).   
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TABLE 2: ASSESSMENT   OF 2nd STUDY 
Item Item 
number 
Description Conformity 
with STREGA 
Title  1 Genetic polymorphisms of the b-
adrenergic system: 
associationwith essential 
hypertension and response to b-
blockade 
 
Introduction 
Background 
rationale 
2 Beta adrenergic receptors are 
involved in several pathophysiological 
functions such as blood pressure (BP). 
Genetic polymorphisms of the bARs 
could lead to functionally different 
products, higher/lower BP values or 
greater/smaller BP fall after treatment 
with b-blockade 
 
Objectives 3 The objectives of the study were: 
(1) to investigate the association of 
polymorphism R389Gb1AR with EH in a 
case–control study and 
(2) to analyze the BP fall after 4 and 8 
weeks of therapy with b-blockers ac-
cording to genotype (pharmacogenetic 
study) in essential hypertensive pa-
tients never treated or untreated for at 
least 6 months 
 
 
 
 
 
 
 
 
 
NO stated 
replication 
Methods 
Study design 4 The study has two phases: 
1stphase: a case-control study.  
Cases: hypertensives 
Controls:  
2nd phase: Pharmacogenetics  Study (a 
cohort study)  
Hypertensives were treated with 
atenolol (pharmacogenetic cohort) and 
the BP fall after 4 and 8 weeks of 
therapy was examined according to 
genotype 
The study was carried oytwith the 
approval of the local Ethical Committee 
and the patients’ written informed 
consent 
 
Setting 5 At the Hypertension and  
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Cardiovascular Prevention Center, 
Sassari, Italy 
Participants 6 1st phase: a case-control study.  
Cases:Hypertensive patients (n = 526) 
white, unrelated, coming from 
genetically homogeneous areas of 
North Sardinia. 
 Selection criteria: 
1) either never treated or out of 
antihypertensive treatment for at least 
6 months.  
2) their high BP had occurred before 
the age of 60 years.  
Controls: (n=192) Normotensives 
white, unrelated North Sardinians, 
Selection criteria: 
1) with history of normotension and BP 
p135/85 on the day of the blood 
sampling. 
2) age: over 60 years. 
3)not having a personal or familiar 
history of both hypertension and 
cardiovascular disease. 
 
2nd phase: Pharmacogenetic Study  
270 hypertensives, were treated with 
atenolol (pharmacogenetic cohort) 
 
 
 
 
 
YES 
Variables 7 1st phase: a case-control studyBP as:  
SBP(systolic),  DBP(diastolic) and MBP 
(mean blood pressure) 
Diagnostic Criteria: 140/90 mmHg 
2nd phase: Pharmacogenetic Study 
Fall  of BP as: DSBP, DDBP and DMBP 
 
Genotype  
Data sources 
measurement 
 
8 BP was measured in the morning every 
2 weeks under patients’ usual diet. 
Three measurements per visit were 
taken by the same nurse in a quiet 
room by using automated electronic 
device. The values of BP were the 
average of the three measurements 
 
Genotyping: Genomic DNA was 
extracted from leukocytes (Talent 
extraction kit, Trieste, Italy). The 
polymorphisms studied were: b1AR: 
R389G,. The primers for R389Gb1AR: 
were as follows: sense—5’-
NO 
 
No 
informationsfor:  
Storage of DNA 
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CCTCTTCGTCTTCTTCAACT-3’,  
antisense—5’-CGGCCGGTCTCCGTG-3’ 
The PCR product was sequenced on 
ABI 377.  
Doubtful calls were double-checked 
and, in case of dubious results, 
repeated or excluded. 
 
 
Bias 
 
9 No matching between cases and 
controls- 
 Stratification by gender and including 
confounders as variables in the 
regression models. 
YES 
No investigation of potential bias 
resulting from pharmacotherapy  
NO 
Study size 10 1st phase: a case-control study 
Initially, included in the study: 
Cases:(Hypertensive patients) n = 526 
Controls: (normotensives)         n=192 
 
Due to laboratory failures, the final 
numbers of individuals in whom 
genotyping was successful  were: 
Cases:(Hypertensive patients) n= 506 
Controls: (normotensives)          n=175 
 
2nd phase Pharmacogenetic Study)  
n= 270 were treated with atenolol 50 
mg b.i.d. (pharmacogenetic cohort).   
The number of genotypes for 
R389Gb1AR was255  
 
YES 
Quantitative 
Variables 
11 Effect of β-blockade YES 
Statistical 
methods 
 
12 
 
 
 
 
 
Intercooled Stata 7.0 for Windows was 
used. 
Normality was tested by Shapiro–Wilk 
and Shapiro–Francia: for non-normally 
distributed variables mathematical 
transformation was attempted and 
parametric/nonparametric tests used 
accordingly Two-tailed t-test and 
Wilcoxon’s rank-sum test were chosen 
as appropriate.  
Genotype frequencies were examined 
by w2 analysis; when expected values 
were below 5, mutant homozygotes 
and heterozygotes were pooled and 
YES 
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Yates correction was applied.  
SBP, DBP and MBP were analyzed also 
as a quantitative trait in the combined 
normotensive and hypertensive 
population introducing age, BMI and 
gender as confounders (ANCOVA);  
For the sex-stratified analysis, the 
same independent variables with the 
exception of gender were used.  
For the post hoc analysis, a P-value of 
0.017 (ie 0.05/3) was considered as 
significant. 
The association between genotype 
and response to treatment was 
evaluated by the change in SBP, DBP 
and MBP vs baseline (DSBP, DDBP and 
DMBP: normal distributions) at 4 and 8 
weeks, adjusted for sex, baseline BPs, 
heart rate and age (ANCOVA).  
  
No data missing.  
Case-control study: No matching 
between cases and controls for age, 
BMI 
Stratification  for gender and including 
these variables in the regression 
models were used to address this 
problem.  
 
No sensitivity analysis was conducted.  
All genotype distributions (for both 
cases and controls) adher to the Hardy-
Weinberg equilibrium.(P=0,45) 
YES 
No method to infer genotypes or 
haplotypes 
NO 
Population stratification by selecting 
cases and controls from the same 
areas 
YES 
Method to control risk of false positive 
findings (double check) 
ΥΕS 
No method to address relatedness 
among subjects 
NO 
Results 
Participants 
 
13 1) 1st phase: a case-control 
studyInitially (genotyping attempted) 
Cases:(Hypertensive patients) n= 526 
Controls: (normotensives)         n=192 
 
YES 
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Genotyped ((genotyping successful) 
Cases:(Hypertensive patients) n= 506 
Controls: (normotensives)          n=175 
 
2) 2nd phase: Pharmacogenetic Study(a  
cohort study) 
 
1st phase: a case-control study 
Due to laboratory failures 
2nd phase: Pharmacogenetic Study(a  
cohort study) 
Due to: laboratory failures 
lost to follow-up 
 
Descriptive data 
 
14 Basic characteristics: given 
Genotyping characteristics: given 
(cases: Arg-Arg:285, Arg-Gly:181, Gly-
Gly:40, total:506 
controls: Arg-Arg:89, Arg-Gly:71, Gly-
Gly:15, total:175) 
YES 
There are no missing data for 
participants 
 
1st phase: a case-control studyOne- 
stage study. No long-term follow-up. 
2nd phase: Pharmacogenetic Study(a  
cohort study) 
4 and 8 weeks 
 
Outcome data 15 1st phase: a case-control study 
Total outcomes: 681 
                  Cases                       Controls 
Arg-Arg:   285 (56.3)                 89(50,8) 
Arg-Gly:    181 (35,8)                  71(40,6) 
Gly-Gly:      40  (7,9)                    15 (8,6) 
Total:        506                             175 
YES 
Main results 
 
16 No association between ADRB1 
Arg389Gly(R389Gb1AR)polymorphisms 
at the b1AR and EH was found, even 
considering gender specificity. 
 
 
Age was used either as a continuous 
variable or as a  categorical with two 
age groups ( <50 yr, and >50 yr) 
 
  
Post hoc analysis YES 
Reference for detailed results available 
elsewhere 
YES 
Discussion 
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Key results 18 No association between ADRB1 
Arg389Gly(R389Gb1AR)polymorphisms 
at the b1AR and EH was found, even 
considering gender specificity. 
Also no effect of the R389Gb1ARto the 
BP fall after 4 and 8 weeks of therapy 
with b-blockers was found in essential 
hypertensive patients never treated or 
untreated for at least 6 months. 
 
Limitations 19 1. Baseline characteristics (age, sex, 
BMI) were different between 
hypertensives and normotensives: 
No matching between cases and 
controls. 
2. Haplotype analysis was not 
performed 
 
Interpretation 20 ------------------------------------------------  
Generalizability 21 ----------------------------------------------------  
Other Information   
Funding 22 The work was supported in part by a 
Research Grant of the Italian Society of 
Hypertension (FF) and by a Grant of 
the Ministry of University and Research 
(MIUR: FIRB #RBNE01724C).   
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TABLE 3: ASSESSMENT   OF 3th STUDY 
Item Item 
number 
Description Conformity with 
STREGA 
Title  1 Effects of polymorphisms in β1-
adrenoceptor and α-subunit of G 
protein on heart rate and blood 
pressure during exercise test. The 
Finnish Cardiovascular Study 
 
Introduction 
Background 
rationale 
2 The Regulation of Cardiovascular 
responses, i.e., blood pressure during 
physical stress is influenced by 
several environmental and genetic 
factors. 
 
Objectives 3 It was tested whether the Arg389Gly 
polymorphism of the β1-adrenergic 
receptor gene ADRB1 modulates 
blood pressure responses during an 
exercise stress test.  
This is the first study to test the 
association between Arg3896Gly 
polymorphism and BP during 
exercise. 
 
 
 
 
 
 
YES 
Methods 
Study design 4 The study is a H-B study. 
The study protocol was approved by 
the Ethical Committee of the Hospital 
District of Pirkanmaa, Finlandand all 
patients gave informed consent 
before the study initiation 
 
Setting 5 The patients underwent exercise 
stress tests at the Tampere University 
Hospital between October 2001 and 
January 2003.  
 
Participants 6 This is a Cohort study. The selection 
criteria were the participants to have 
technically successful exercise test 
and acquired genotypic samples.  
 
YES 
Variables 7 BP as:  SAP and DAP 
Diagnostic Criteria: 140/90 mmHg 
 
Genotype  
Data sources 
measurement 
 
8 Three values of SAP and DAP were 
taken for analysis: resting, maximal 
during the exercise and 4 min after 
the test (recovery). During the 
exercise test (using a bicycle 
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ergometer with electrical brakes), 
SAP and DAP were measured with a 
brachial cuff every second minute. 
Genomic DNA was extracted from 
peripheral blood leukocytes using a 
commercially available kit and 
QiagenBioRobot M48 Workstation, 
according to the manufacturer’s 
instructions (Germany).  
DNA samples were genotyped by 
employing the 5 nuclease assay and 
fluorogenic allele-specific TaqMan 
MGB probes, using the ABI Prism 
7900HT Sequence Detection System 
(Applied Biosystems, Foster City, CA). 
The nucleotide sequences of primers 
and probes used in the PCR were 
deduced from published sequences 
deposited in the GenBank and Celera 
databases and synthesized by Applied 
Biosystems. PCR reaction containing 
genomic DNA, 1 Universal PCR 
Master Mix, 900 nM of each primer, 
and 200 nM of each probe was 
performed in 384-well plates by using 
the standard protocol in a total 
volume of 5 l. End-point fluorescence 
was measured and genotype calling 
was carried out by the allelic Error 
discrimination analysis module after 
the PCR resulted in clear 
identification of Arg389Gly 
polymorphisms of ADRB1.  
Negative and positive controls 
(known genotypes) and random 
duplicates were used as quality 
control. 
NO 
 
No information 
for:  
Storage of DNA 
Error rates 
Call rates 
Bias 
 
9 No information for potential sources 
of bias and addressing them 
NO 
No investigation of potential bias 
resulting from pharmacotherapy  
NO 
Study size 10 The participant pool consisted of the 
patients undergoing exercise stress 
tests at the Tampere University 
Hospital between October 2001 and 
January 2003. All of the consecutive 
patients coming to take an exercise 
stress test and willing to participate 
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in the study were recruited. 
Finally, the 890 patients with 
technically successful exercise tests 
and acquired genotypic samples were 
included in the study (563 men and 
327 women). 
Quantitative 
Variables 
11 Effect of β-blocking agents: The 
patients takingβ–blockingagents had 
a lower SAP (95% CI of difference: 11 
to 19 mmHg) and tended to have 
lower DAP (95% CI of difference: 0 to 
3 mmHg) at maximal load, than those 
not taking -blockers  
 
YES 
Statistical 
methods 
 
12 
 
 
 
 
Statistical analyses were performed 
with the SPSS release 12.0.1 
forWindows (SPSS, Chicago, IL). 
 
The longitudinal exercise stress test 
data were analyzed by repeated-
measurement analyses of variance 
(RANOVA) using the genotypes as 
categorical factors and the HR, SAP, 
and DAP values measured at different 
points in time (resting, exercise, and 
recovery) as dependent repeated 
variables 
The SAP and DAP values were 
compared between the genders with 
Student’s t-test for independent 
samples. 
YES 
The study population was analyzed as 
a whole and divided based on gender. 
Since BMI is often an explaining 
factor for different results in men and 
women, BMI was used as covariate in 
the analyses.  
Αge, BMI, β-adrenergic antagonism 
were used as covariates. The 
interaction between these covariates 
and the variant was calculated.  
A P= 0.05 was considered statistically 
significant, and 95% confidence 
intervals (CI) were calculated  
 
No data missing.  
Cohort Study: no probability of loss to 
follow-up, because of the study 
design 
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No sensitivity analysis was 
conducted. 
 
All genotype distributions adhered to 
the Hardy-Weinberg equilibrium. 
YES 
No method to infer genotypes or 
haplotypes 
NO 
Homogeneity of Finnish population YES (although it 
was not stated ) 
No method to control risk of false 
positive findings 
NO 
No method to address relatedness 
among subjects 
NO 
Results 
Participants 
 
13 890 patients: 563 men and 327 
women, during the whole study  
 
One-stage study.  
One-stage study. No changes in the 
participants number, during the study 
 
Descriptive data 
 
14 Patient characteristics: given 
Genotyping characteristics: given 
(Arg-Arg:523, Arg-Gly:307, Gly-
Gly:60) 
YES 
No missing data for participants   
One-stage study. No long-term 
follow-up. 
 
Outcome data 15 Total outcomes: 890  
Arg-Arg:523 
Arg-Gly:307 
Gly-Gly:60 
YES 
Main results 
 
16 Among all subjects, Gly389 
homozygotes tended to be more 
likely to have hypertension (OR- 1.69, 
95% CI 1.00 –2.86, P= 0.050) 
compared with Arg389 carriers. 
Arg389Gly polymorphism of ADRB1 
affected maximal SAP during exercise 
(P 0.04, ANOVA,) and the change in 
SAP from rest to maximal (P 0.03, 
ANOVA,). 
Αge, BMI, β-adrenergic antagonism 
were considered as confounders and 
used as covariates. The interaction 
between these covariates and the 
variant was calculated.  
Since BMI is often an explaining 
factor for different results in men and 
women, BMI was used as covariate in 
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the analyses. 
Age was used either as a continuous 
variable or as a  categorical with 
three  age groups ( <40 yr, 40 – 60 yr, 
and >60 yr) 
 
  
Other analyses 
 
17 Effect of gender. Men had a lower HR 
than women at rest(CI: 0.3 to 3.2 
beats/min) and during maximal 
exercise (0.7 to 7.8 beats/min); they 
also had lower SAP at rest (CI: 4 to 9 
mmHg) but not at exercise (CI: 0 –7 
mmHg). DAP did not differ between 
the genders.  
Effect of age. The higher the age 
group, the lower the HR atall three 
phases. At rest and recovery, the SAP 
values increased in line with 
increasing age: the higher the age 
group, the higher the SAP (P 0.001 for 
both time points, ANOVA). However, 
during exercise, the middle-aged 
subjects had the highest SAP (P=0.01, 
ANOVA). DAP was higher in the 
middle-aged than the younger and 
older age groups at rest as well as 
during exercise (P=0.01, ANOVA), and 
the two oldest groups had higher DAP 
than the youngest ( 40 yr) at recovery 
 
No reference for detailed results 
available elsewhere 
 
Discussion 
Key results 18 In all subjects, and in men and 
women separately, no statistically 
significant interaction was found for 
the ADRB1 Arg389Gly polymorphism 
in relation to SAP and  DAP responses 
over the three study phases 
(RANOVA, P=0.10 for interaction in all 
analyses where age, BMI, and β-
adrenergic antagonism were used as 
covariates). The Gly389 homozygotes 
had higher maximal SAP during 
exercise than those with at least one 
Arg389 allele; consequently, the 
change of SAP from the resting state 
to the maximal had the same pattern.  
 
Limitations 19 No limitation is referred  
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Interpretation 20 --------------------------------------  
Generalizability 21 The largest available study 
populations, endorse the negative 
finding, but they also support the 
view that the ADRB1 Arg389Gly 
polymorphism may modulate 
hemodynamics in certain situation.. 
 
 
Other Information 
Funding 22 Financial support was received from 
the Medical Research Fund of 
Tampere University Hospital, the 
Finnish Foundation for Cardiovascular 
Research, the Academy of Finland 
(Grant 104821), and the Emil 
Aaltonen Foundation, Finland. 
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TABLE 4: ASSESSMENT   OF 4th STUDY 
Item Item 
number 
Description Conformity with 
STREGA 
Title  1 Association between essential 
hypertension and polymorphisms of 
beta 1-adrenergic receptor gene 
G1165C (Gly389Arg) in Chinese 
Mongolian population 
 
Introduction 
Background 
rationale 
2 The prevalence of hypertension, 
cerebrovascular diseases etc. are 
higher in Mongolian population 
because of the influence of various   
factors including environmental, 
genetic, diet etc. 
 
Objectives 3 To analyze the association between 
Arg3896Gly polymorphism and 
essential hypertension in Mongolian 
population 
 
 
 
NO  
NO stated 
replication 
Methods 
Study design 4 A cross-sectional study 
 
 
Setting 5 The study was carried out  in the 
Department of Neurology, The First 
Affiliated Hospital of Inner Mongolia 
Medical College, from February 2003 
to March 2005  
 
Participants 6 239 Mongolian residents, in three 
groups 
122 :essential hypertension group 
   51: simple increase of SBP 
117 :normal BP group 
YES 
Variables 7 BP as:  SBP  
Diagnostic Criteria: 140/90 mmHg 
 
Genotype  
Data sources 
measurement 
 
8 Three values of BP were taken 
continuously with a hemomanometer 
 
Peripheral venous blood (5ml) was 
drawn, anticoagulated with heparin, 
red blood cells were destroyed with 
low-permeability method and white 
blood cellswere separated. DNA was 
extracted from peripheral white 
blood cells using a kit. 
NO 
No information 
for:  
Storage of DNA 
Error rates 
Callrates 
Bias 9 No information for potential sources NO 
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 of bias and addressing them 
No investigation of potential bias 
resulting from pharmacotherapy  
NO 
Study size 10 239 participants  
Quantitative 
Variables 
11 ----------------------------------------  
Statistical 
methods 
 
12 
 
 
 
 
Statistical analyses were performed 
with the SPSS release 11.5 
The measurement data were 
expressed as Mean± SD. 
The univariate analysis of variance 
was applied in the sample 
comparison among groups. 
Genotypes and allele frequencies 
were compared with the chi-square 
test.The odd ratio (OR) and 95% 
confidence intervals (CI) were 
calculated  
YES 
 
 
 
No data missing.  
Cross-sectional Study: no probability 
of loss to follow-up, because of the 
study design 
 
No sensitivity analysis was 
conducted. 
 
All genotype distributions adhered to 
the Hardy-Weinberg equilibrium. 
YES 
No method to infer genotypes or 
haplotypes 
NO 
No method to address population 
stratification 
NO 
No method to control risk of false 
positive findings 
NO 
No method to address relatedness 
among subjects 
NO 
Results 
Participants 
 
13 239 Mongolians  
Cross-sectional Study  
No one missed  
Descriptive data 
 
14 Demographic characteristics: given 
Genotyping characteristics:given 
 
 
YES 
There are no missing data   
One-stage study.  
No long-term follow-up. 
 
Outcome data 15 Number in each genotype category is YES 
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reported 
Main results 
 
16 In Mongolian Population, the 
distribution of the genotypes and 
alleles ofthe ADRB1 Arg389Gly 
polymorphismhave no obvious  
differences between normotensives, 
patients with essential 
hypertensionand subjects with simple 
increase of SBP. 
 
Other analyses 
 
17 --------------------------------------------------  
No reference for detailed results 
available elsewhere 
 
Discussion 
Key results 18 In Mongolian Population, the ADRB1 
Arg389Gly polymorphism may be not 
a genetic mark of essential 
hypertensionand simple high SBP 
 
Limitations 19 No limitation is referred  
Interpretation 20 -----------------------------------------  
Generalizability 21 --------------------------------------------  
Other Information 
Funding 22 No source of funding for the present 
study is included in the article. NO 
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TABLE 5: ASSESSMENT  OF 5th STUDY 
Item 
Item 
number 
Description Conformity 
with 
STREGA 
Title  
 
1 Modifying effects of the R389G β1-
adrenoceptor polymorphism on 
restingheart rate and blood pressure 
in patients with obstructive sleep 
apnoea (OSA) 
 
Introduction 
Background 
rationale 
2 OSA stimulates sympathetic nervous 
activity and elevates resting blood 
pressure, likely related with 
genotypes of the β1-
adrenoreceptorR389G polymorphism 
 
Objectives 3 The aim was to investigate whether 
theArg389β1-adrenoceptor phenotype 
modifies blood pressure inpatients 
with moderate-to-severe OSA.  
Also, a second goal was to examine 
whether the effect of CPAP 
(continuous positive airway pressure) 
therapy on BP in a subgroup of OSA 
patients, was modulated by this 
polymorphism 
First attemption in this field 
 
 
 
 
 
 
 
 
 
 
 
YES 
Methods 
Study design 4 The study protocol was approved by 
the Local Ethics Committee  at  Ruhr  
University Bochum in  Germany. 
Written consent for participation was 
available. 
 
 
Setting 5 Patients were consecutively enrolled 
from 1999–2001 in the sleep 
laboratory of the Marienhospital 
Herne (Ruhr University  Bochum,  
Bochum,  Germany).   
 
Participants 6 309 untreated OSA patients. Arterial 
hypertension  was diagnosed in 167 
patients. So:  
Cases: 167 Hypertensive   
Controls : 142 Normotensives 
YES 
Variables 7 BP as:  SBP (systolic) and 
DBP(diastolic) 
 Diagnostic Criteria: 140/90 mmHg 
 
Genotype  
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Data sources 
measurement 
8 BP was measured three times a day 
(08:00, 14:00 and 19:00 hours) for1 
min during the hospital visits for 
polysomnography bypalpitation (1 
min) and the Riva Rocci method. 
Patientswere rested for at least 10 
min before measurements 
wereperformed. by 
thenurses/technical assistants in the 
sleep laboratory, whowere 
introduced to the procedures but 
were blinded to thepurpose of the 
study. The means of three 
measurementswas used for further 
calculations. 
 
 
Genotyping: 
Peripheral blood samples from the 
patients were obtained with their 
informed consent. Primers were 
synthesized in order to amplify the 
522 bpfragment in which the R389G 
polymorphism was at position 159: 5_ 
-CGCTCTGCTGGCTGCCCTTCTTCC-3_ 
(sense)and 
5_TGGGCTTCGAGTCCTGCTATC-3_ 
(anti-sense). 
PCR was carried out in a final 
volume of 10 µl with 50 ng of DNA, 
200 µM dNTP and 1 unit of Taq 
polymerase. PCR cycling started with 
initial denaturation for 5 min at 94 ◦ 
C. The annealing temperature of the 
first cycle was 61o C, second cycle was 
58 o C, and the remaining 26 cycles 
were 55 o C. The annealing time was 1 
min. Extension was performed at 72 o 
C, for 1 min (final extension, 5 min). 
The PCR fragment was treated with 
the restriction endonuclease Mva1 
(EcoR11) which fails to digest the 
Arg389 allele because of the G → C 
transition. Digested DNA was 
electrophoresed on 1.5% (w/v) 
agarose gels. The restriction 
fragments of the Arg389 allele were 
311, 84, 58, 45 and 24 bp long. The 
Gly389 allele harbours an additional 
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restriction site so that the 311 bp 
fragment is digested into 135 and 176 
bp fragments  
 
Bias 9 No information for potential sources 
of bias and addressing them 
NO 
No investigation of potential bias 
resulting from pharmacotherapy  
NO 
Study size 10 309 subjects, from which 
167 Hypertensive  (cases) 
142 Normotensives (controls) 
 
Quantitative 
Variables 
11 The effect of CPAP (continuous 
positive airway pressure) therapy on 
BP in a subgroupof OSA patients 
 
Statistical 
methods 
 
12 
 
 
 
 
Demographic characteristics of the 
OSA patients were compared with 
the different genotypes by using a 2 × 
2 contingency table and χ2test, Mean 
values of numeric variables were 
compared for each genotype by 
ANOVA. The homogeneity of the 
variances was confirmed by the 
Levene’s test.  
A multi-variate linear/logistic 
regression model was established to 
investigate an independent influence 
of the severity of OSA (represented 
by AHI) and the R389G poly-
morphism on BP and the prevalence 
of hypertension. 
In the follow-up cohort of 148 
patients, the number of Gly389 
homozygotes was small (n= 8). 
Therefore, in an additional model, 
patients with R389G and G389G 
genotypes were combined into one 
group. Differences between the two 
genotype groups [R389R and (R389G 
+ G389G)] were calculated by 
Student’s t-test. 
 
 
NO  
 
Software 
used not 
stated 
  
Method to infer genotypes or 
haplotypes 
YES 
No method to address population 
stratification 
NO 
No method to control risk of false NO 
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positive findings 
No method to address relatedness 
among subjects 
NO 
Results 
Participants 
 
13 309 subjects, from which 
167 Hypertensive  (cases) 
142 Normotensives (controls) 
 
No changes in the participants 
number 
 
Descriptive data 
 
14 Information by genotype is given  
  
Outcome data 15 Number in each genotype category is 
reported 
ΥΕS 
Other analyses 
 
17 --------------------------------------------------  
  No reference for detailed results 
available elsewhere 
 
Main results 
 
16 The β1-adrenoceptor R389G 
polymorphism did not influence the 
BP in untreated OSA patients. 
However, it may modify the beneficial 
effects of CPAP therapy on BP 
 
  
No reference for detailed results 
available elsewhere 
 
 
Discussion 
Key results 18 The R389R polymorphism was not 
associated with higher BP in 
untreated OSA patients. 
 
Limitations 19 1)The study was not designed to 
dissect thediffering influence of the 
R389G polymorphism on BP. 
2)Comparatively few measurements 
per patient. 
 
Interpretation 20 
This finding could be interpreted as 
further evidence that the R389G 
polymorphism of the β1-adrenoceptor 
gene has only minor relevance in vivo. 
 
 
Generalizability 21 ----------------------------------  
Other Information 
Funding 22 The study was supported by FoRUM 
(Forschungs-forderung¨ der Ruhr-
Universitat¨ Bochum, Medizinische 
Fakultat)¨.   
 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 12:46:38 EET - 137.108.70.7
TABLE 6: ASSESSMENT   OF 6th STUDY 
Item Item 
number 
Description Conformity with 
STREGA 
Title  1 Studies of associations between the 
Arg389Gly polymorphism of the β1-
adrenergic receptor gene (ADRB1) and 
hypertension and obesity in7677 
Danish white subjects 
 
Introduction 
Background 
rationale 
2 Activation of the β1-adrenergic 
receptor (ADRB1) enhances cardiac 
output. Analysis of the association of 
the functional ADRB1 Arg389Gly 
variant with hypertension has given 
ambiguous results. 
 
Objectives 3 To clarify the potential impact of the 
Arg389Gly variant on hypertension in 
the general population. 
 
It is a replication 
 
 
 
 
YES 
Methods 
Study design 4 Case-control studies and quantitative 
trait analyses were carried outin 7677 
Danish Caucasians who were 
genotyped for the Arg389Gly variant  
 
Setting 5   
Participants 6 The ADRB1 Arg389Gly (dbSNP 
rs1801253) variant was genotyped in 
7677 Danish whites subjects from three 
study groups: 
(i) a population-based cohort (Inter99) 
of middle-aged Danish white 
subjects living in the greater 
Copenhagen area and studied at the 
Research Centre for Prevention and 
Health (n = 6257) 
(ii)  a group of Type 2 diabetic patients 
identified through the outpatient 
clinic at Steno Diabetes Center (n = 
1088) 
(iii) a population-based group of 
middle-aged glucose-tolerant subjects 
recruited from the Research Centre 
for Prevention and Health (n = 346). 
 
YES 
Variables 7 Blood pressure (BP )as:Systolic(SBP)  
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Diastolic(DBP)  and mean arterial BP 
MABP =2 × [diastolic blood pressure + 
systolic blood pressure] /3 
Diagnostic Criteria: 140/90 mmHg 
Genotype  
Data sources 
measurement 
 
8 Blood pressure was measured twice in 
the morning after 10 min of rest before 
blood drawing, with the participant in a 
supine position with slightly elevated 
head using a Hawksley random zero 
mercury sphygmomanometer with an 
appropriate cuff size. Systolic blood 
pressure was taken at the return of 
arterial sounds (Korotkoff phase I) and 
diastolic blood pressure at the 
disappearance of sounds (Korotkoff 
phase V).MABP was calculated 
 
Genotyping of the ADRB1 Arg389Gly 
variant (dbSNP rs1801253) was 
performed using a chip-based matrix-
assisted laser desorption/ionization 
time-of-flight (MALDI-TOF) mass 
spectrometry (DNA MassARRAY; 
Sequenom, San Diego, CA, USA) of PCR-
generated primer extension products. 
 
 
The overall success rate for the 
genotyping was> 98%. Of 182 samples 
genotyped in duplicates, no genotype 
discrepancies were observed. 
NO 
 
No information 
for: 
Extraction of 
DNA 
Storage of DNA 
Genotyping 
Platform 
 
 
 
 
YES for errors 
Bias 
 
9 No information for potential sources of 
bias and addressing them 
NO 
No investigation of potential bias 
resulting from pharmacotherapy  
NO 
Study Size  10 Final number: 6499  (cases n = 2518; 
control n = 3981) 
 
Quantitative 
Variables 
11 -----------------------------------------------------  
Statistical 
methods 
 
12 
 
 
 
 
All analyses were performed using 
Statistical Package for Social Science 
(SPSS; Chicago, IL, USA) version 13.0and 
RGui version 2.10.  
Fisher’s exact test was applied to 
examine differences in minor allele 
frequencies (MAF) and genotype 
distributions between affected and 
 
YES 
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unaffected subjects. Logistic regression 
with adjustment for sex and age was 
also used to test for differences in 
genotype distribution. A general linear 
model was used to test quantitative 
variables (or transformed variables) for 
differences between genotype groups. 
Genotype and sex were considered as 
fixed factors and age as covariates.  
A P-value <0.05 was considered to be 
significant. 
 
 
 
 
 
 
YES 
No data missing.  
Case-control  Study   
No sensitivity analysis was conducted.  
All genotype groups obeyed Hardy–
Weinberg equilibrium. 
Yes 
No method to infer genotypes or 
haplotypes 
NO 
No method to address population 
stratification 
NO 
Method to control risk of false positive 
findings (Of 182 samples genotyped in 
duplicates, no genotype discrepancies 
were observed)  
YES 
No method to control relatedness NO 
Results 
Participants 
 
13 Total number: 6499  (cases n = 2518; 
control n = 3981) 
 
Number of missing participants is given  
  
Descriptive data 
 
14 Patient characteristics: given 
 
 
Genotyping characteristics: given 
 
YES 
Outcome data 
15 Number in each genotype category is 
reported 
ΥΕS 
Main results 
 
16 No association of the hypertension with 
allele frequencies (P = 0.3) or genotype 
distribution (P = 0.5) was found. 
 
Other analyses 
 
17 In the quantitative trait analyses, 
individuals carrying the Gly allele had 
slightly but significantly lower diastolic 
(Arg/Arg = 81.9 mmHg vs. Gly-allele 
carriers = 81.5 mmHg) and systolic 
(Arg/Arg = 129.4 mmHg vs. Gly-allele 
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carriers = 128.8 mmHg) blood pressure 
as well as a lower mean arterial blood 
pressure.  
Discussion 
Key results 18 The ADRB1 Arg389Gly variant is most 
likely not to be a major contributor to 
the development of hypertension. 
However, it is possible that the Arg 
allele may contribute by causing a 
minor increase in systolic and diastolic 
blood pressure levels in a middle-aged 
white population, although the effect is 
not powerful enough to cause 
hypertension. 
 
Limitations 19 --------------------------------------------------  
Interpretation 20 ------------------------------------------  
Generalizability 21 ----------------------------------------------  
Other Information 
Funding 22 The study was supported by the Danish 
Medical Research Council, the Danish 
Diabetes Association, the Danish Heart 
Foundation, the Velux Foundation, and 
the European Economic Community 
(EUGENE2 LSHM-CT-2004–512013).  
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TABLE 7: ASSESSMENT   OF 7th STUDY 
Item 
Item 
number 
Description Conformity 
with 
STREGA 
Title  
 
1 Genetic variants of β1-adrenoceptor gene 
polymorphisms (Ser49Gly and Arg389Gly) and 
essential hypertension in a South Indian Tamil 
population 
 
Introduction 
Background 
rationale 
2 Very few studies have described the role of β1-
adrenoceptor gene polymorphisms in hypertension 
worldwide and so far there are few data relevant to 
the Indian population.  
The genetic profile of the β1-ADRB has not yet been 
documented for any Indian population. 
 
Objectives 3 The aim was to determine the association between 
β1-adrenoceptor Arg389Glygene polymorphism and 
the susceptibility of individuals to essential 
hypertension in a south Indian Tamil population. 
Replication  
 
 
 
 
 
YES 
Methods 
Study design 4 The present case-control study included patients 
with essential hypertension (cases) and healthy 
volunteers (controls) from the Tamil population.  
 
Setting 5 The present study was performed from January 
2005 to February 2008 from outpatient clinics of 
hypertension and internal medicine (Jawaharlal 
Institute of Post graduate Medical Education and 
Research (JIPMER) Hospital, Pondicherry, India). 
The control group consisted of 444 healthy 
volunteers (201 men and 243 women) aged 30–60 
years. These subjects had no personal or family 
history of hypertension in first-degree relatives. 
Patient characteristics, such as bodyweight, height 
and drug history, were recorded. All participants 
were interviewed using a standardized 
questionnaire with regard to their lifestyle, 
smoking, alcohol consumption and drug intake. 
 
Participants 6 Cases:438 unrelated essential hypertensive 
patients (213 men /225 women) aged 30–60 ys,  
being resident in Tamilnadu &Pondicherry going 
back for at least three generations.  
Selection criteria: Patients receiving 
 
YES 
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antihypertensive medications for more than 3 
months or newly diagnosed hypertensive patients 
with systolic blood pressure (SBP) > 140 mmHg 
and/or diastolic blood pressure (DBP) > 90 mmHg 
on two or more visits  
 
Controls: 444 healthy volunteers (201 men/243 
women) aged 30–60 yrs, with no personal or family 
history of hypertension in first-degree relatives and 
had SBP < 130 mmHg and DBP <85 mmHg 
 
 
Variables 7 BP as:  SBP and DBP 
Diagnostic Criteria: 140/90 mmHg (hypertensive) 
and 130/85 mmHg (non-hypertensive)   
Genotype  
Data sources 
measurement 
8 Blood pressure was measured in the right arm after 
subjects had rested for 10 min using a standard 
sphygmomanometer; the average of three 
readings, taken 2 min, apart was recorded. 
 
Genotyping: A 5 mL venous blood sample was 
collected using EDTA as an anticoagulant. Genomic 
DNA was extracted from peripheral leucocytes 
using the standard phenol: chloroform method. 
Genotyping for Arg389Gly was performed using a 
Real Time Thermocycler (ABI Prism 7700; ABI, 
Foster City, CA, USA) with a Taqman SNP 
genotyping assay method. This technique uses 
fluorogenic 5′ nuclease chemistry (also known as 
Taqman probe-based chemistry) to enable 
detection of specific polymerase chain reaction 
(PCR) products. The SNP genotyping assay 
identification details used (Applied Biosystems) 
were and C__8898494-10 for Arg389Gly.The PCR 
reaction was performed in duplicate in 20L final 
volume, containing 10L Taqman Universal PCR 
master mix (2×), 0.75 L of 20× working stock of SNP 
genotyping assay and 4.5 L genomic DNA (diluted in 
DNase-free water and 4.75 L deionized water). The 
thermocycler conditions included one cycle at 50°C 
for 2 min and one cycle at 95°C for 10 min to 
activate the AmpliTaq Gold polymerase, followed 
by 40 cycles of denaturation at 92°C for 15 s and 
annealing/extension at 60°C for 1 min. The allelic 
discrimination analysis was performed using 7700 
SDS software (Applied Biosystems, Foster City, CA, 
USA). 
 
Bias 9 No information for potential sources of bias and NO 
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addressing them 
No investigation of potential bias resulting from 
pharmacotherapy  
NO 
Study size 10 The study size remained the same during the whole 
time. 
 
Quantitative 
Variables 
11 -----------------------------------------------------------------  
Statistical 
methods 
 
12 
 
 
 
 
Statistical analysis was performed using the SPSS 
software (Windows version release 13; SPSS, 
Chicago, IL, USA) and GraphPadInstat software 
(GraphPad Software, San Diego, CA, USA).  
Demographic details of hypertensive patients and 
controls that were continuous variables were 
compared using Student’s unpaired t-test, whereas 
dichotomous variables were analyzed using χ2 
and/or Fisher’s exact test. 
 Differences in allele frequencies and genotype 
distributions between hypertensive patients and 
normotensives controls were compared by χ2 
and/or Fisher’s exact test.  
The association between genotypes and the risk of 
hypertension was analyzed by calculating the crude 
odds ratio (OR) and 95% confidence interval (95% 
CI) using χ2 and/ or Fisher’s exact test. The adjusted 
OR was calculated using unconditional logistic 
regression and the low-risk genotype was 
designated as the reference category. For analyzing 
gene–gene interactions, stratified variables were 
generated and included the logistic model, 
simultaneously with appropriate indicator 
variables. Linkage disequilibrium values for the pair 
of dimorphisms were measured using Helix Tree 
software (Golden Helix, Bozeman, MT, USA). The 
haplotype of Arg389Gly was constructed using 
Helix tree software using the EM algorithm.  
The genotype frequencies observed were 
compared with the expected frequencies to check 
for Hardy– Weinberg equilibrium  
P < 0.05 was set as the level of significance. 
 
YES 
  
  
Matching of cases and controls:  
No significant differences were observed in sex 
distribution, BMI, alcohol consumption, 
triglycerides and HDL- cholesterol levels between 
patients and controls. 
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Patients and controls were not age matched. 
No sensitivity analysis was conducted.  
No genetic information for Indian , yet NO 
No method to infer genotypes or haplotypes NO 
The subjects were all of the same ethnic group to 
control for population stratification. 
ΥΕS 
No method to control risk of false positive findings NO 
No method to address relatedness among subjects NO 
Results 
Participants 
 
13 The study size remained the same during the whole 
time the study was conducted. 
 
  
Descriptive 
data 
 
14 Patient characteristics: given 
 
 
Genotyping characteristics: given 
 
 
Outcome data 15 Number in each genotype category is reported ΥΕS 
Main results 
 
16 There were no significant differences in the 
genotypes and allele frequencies for Arg389Gly 
between hypertensive patients and controls. 
The unadjusted ORs were 1.1(95% CI: 0.8–1.4, 
P=0.7) for Arg/Gly  and 1.3(95% CI:  0.8–2.2, P=0.3) 
for Gly/Gly 
 
  
Other analyses 
 
17 Gender-specific analysis was performed by 
comparing the hypertensive men / women with 
their respective control  
 
Potential confounders: sex, age, BMI  
No reference for detailed results available  
Discussion 
Key results 18 There were no significant differences in the 
genotypes and allele frequencies for Arg389Gly 
between hypertensive patients and controls. 
 
Limitations 19 A limitation of the present study is that 
hypertensive patients and controls were not age 
matched. This does not appear to be a major 
drawback because the age of the control group was 
higher(47.4±0.4 years) than that of the 
hypertensive patient group (44.9±0.4 years) 
 
Interpretation 20 The results of the present study deviate from those 
reported in previous case-control study. This could 
be attributed to variations in environmental 
factors, in addition to differences in the selection of 
hypertensive patients and controls, sample size, 
age, BMI and other environmental factors. 
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Generalizability 21 The strength of the present study lies in its 
judicious selection of unrelated hypertensive 
patients and controls from the homogeneous 
population. 
 
Other Information 
Funding 22 This study was funded by the Department of 
Biotechnology–NewDelhi 
(D.O.No.BT/PR4076/Medical/12/163/2003 dated 
1/12/2004).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 12:46:38 EET - 137.108.70.7
TABLE 8: ASSESSMENT   OF 8th STUDY 
Item 
Item 
number 
Description Conformity 
with 
STREGA 
Title and 
Abstract 
 
1 Polymorphisms of the b1-adrenergic 
receptor gene are associated with 
essential hypertension in Chinese. 
 
Introduction 
Background 
rationale 
2 Blood pressure is determined by two 
factors: cardiac output and peripheral 
resistance, which are regulated by 
the sympathetic nervous system. The 
b1-adrenergic receptor (ADRB1) plays 
a pivotal role in mediating signal 
transduction of the sympathetic-
adrenal system, which is involved in 
the regulation of cardiac output and 
peripheral resistance. 
 
Objectives 3 The goal of the present study was to 
investigate whether the functionally 
important Arg389Gly polymorphism 
of the ADRB1 gene was associated 
with hypertension in Chinese. 
 
First, with two studies in two 
independent populations 
 
 
 
 
 
 
YES 
Methods 
Study design 4 The hypothesis was tested in two 
independent case-control studies, 
one comprised 481 patients with 
hypertension and 529 control 
subjects, and the other study 
comprised 212 patients and 325 
control subjects. Informed consent 
was obtained from all individuals 
 
Setting 5 The subjects of the first study were 
comprised of outpatients from a 
hospital in Shijiazhuang city, Hebei 
province, People’s Republic of China. 
In the second study, the population 
was from a community center in 
Beijing Fengtai District. 
 
Participants 6 1st Case-control study :The subjects 
consisted of 481 patients with mild 
and moderate EH    and  529 age- and 
gender-matched controls from the 
YES 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 12:46:38 EET - 137.108.70.7
same area. 
2nd Case-control study :The 
population was from a community 
center in Beijing Fengtai District. The 
study population was comprised of 
212 cases with hypertension and 325 
control subjects and was recruited 
using the same criteria as the first 
study. 
Variables 7 BP (blood pressure),  
Genotype  
Data sources 
measurement 
 
8 Blood pressure was measured by the 
same investigator using the right arm 
with a mercury sphygmomanometer 
and standard techniques after at least 
5 min of rest in a sitting position. 
 
Genotyping 
Peripheral blood (10 mL) was 
collected into tubes containing 
trisodium citrate (final concentration 
in blood, 0.026 mol/L), and 
centrifuged at 3000 g for 10 min at 
room temperature. The plasma and 
‘‘buffy-coat’’ were separated and 
stored in a 1.5-mL EP tube at –708C. 
All assays were performed in 
duplicate. DNA was extracted from 
the ‘‘buffy-coat’’ as described 
previously (13), and stored at –708C 
before use. Single nucleotide 
polymorphism Arg389Gly was 
analyzed by amplification of a 530-
base pair (bp) sequence with primers: 
59-CGC TCT GCT GGC TGC CCT TCT 
TCC -39 and 59-TGG GCT TCG AGT 
TCA CCT GCT ATC-39 (6). The 
polymerase chain reaction (PCR) 
products were digested with BcgI 
(New England Biolabs, Beverly, MA, 
USA); only one band for the 
Gly389Gly homozygote, two DNA 
fragments of 376 bp and 154 bp were 
obtained for the Arg389Arg 
homozygote on 3% agarose gel and 
three bands for the Arg389Gly 
heterozygote.  
The sequence was confirmed by 
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bidirectional sequencing of 200 
samples with ABI Prism 3730 Genetic 
Analyzer (Applied Biosystems Inc.) 
(14), and  the reproducibility was 
100%. 
Bias 
 
9 No information for potential sources 
of bias and addressing them 
 
No investigation of potential bias 
resulting from pharmacotherapy  
 
 Study Size 10 1st Case-control study  
481 cases 
529 controls  
2nd Case-control study  
212 cases  
325 control 
 
Quantitative 
Variables 
11 --------------------------------------  
Statistical 
methods 
 
12 
 
 
 
 
Statistical analysis was performed 
with the SPSS 13.0 package. 
 
Data are expressed as means±SD.  
The x2-test was used for testing 
categorical variables, the Hardy-
Weinberg equilibrium of the 
polymorphisms, and genotype/allele 
frequencies.  
Quantitative variables between 
groups were tested with  Student’s 
test. 
 The association of SNPs with 
hypertension was analyzed using 
multivariate logistic regression. The 
analysis was adjusted for age, gen-
der, BMI, smoking, glucose, HDL-C, 
LDL-C, TC, TG alcohol consumption, 
and family history of hypertension. 
 A two-tailed p=0.05 was considered 
significant.  
YES 
  
No data missing.  
  
No sensitivity analysis was 
conducted. 
 
All genotype distributions adhered to 
the Hardy-Weinberg equilibrium. 
YES 
No method to infer genotypes or 
haplotypes 
NO 
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The subjects were all of Han ethnic 
group to control for population 
stratification. 
ΥΕS 
No method to control risk of false 
positive findings 
NO 
No method to address relatedness 
among subjects  
NO 
Results 
Participants 
 
13 1st Case-control study  
481 cases 
529 controls  
2nd Case-control study  
212 cases  
325 control  
 
No changes in the participants 
number, during the study 
 
Descriptive data 
 
14 Information by genotype is given YES 
No missing data for participants  
Outcome data 
15 Number in each genotype category is 
reported 
YES 
Main results 
 
16 
 
1st Case-control study  
The Arg389Arg genotype of the 
ADRB1 gene was associated with risk 
of hypertension (odds ratio (OR)= 
1.77, 95% confidence interval (CI) 
1.09–2.98) 
2nd Case-control study  
The association was replicated in the 
second independent population (OR 
1.65, 95% CI 1.07–2.89)  
 
 
The patients with the Arg389Arg 
genotype had significantly higher 
diastolic blood pressure (DBP) than 
did those with Arg389Gly genotype as 
well as those with Gly389Gly 
genotype, in both studies No 
association was seen between 
systolic blood pressure (SBP) and any 
of the three genotypes at amino acid 
position 389 in hypertensive patients 
 
Other analyses 
 
17   
  
  
Discussion 
Key results 18 The Arg389Gly polymorphism of the  
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ADRB1 gene confers higher risk for 
hypertension. Hypertensive patients 
with Arg389Arg variants had 
significantly increased DBP.  
Limitations 19 Results need to be confirmed in a 
larger sample of individuals.  
 
Interpretation 20 The maximal increase in cyclic 
adenosine monophosphate caused by 
isoprenaline was significantly larger in 
Arg389 than in Gly389 ADRB1 cells. 
The increased in vivo activity of the 
Arg389 variant of ADRB1 could be 
expected to lead to higher cardiac 
output, and could therefore explain 
the association between the Arg389 
allele and hypertension 
 
Other Information 
Funding 22 No source of funding for the present 
study is included in the article. NO 
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ABBREVIATIONS 
 
ADRB1 :β1-Adrenergic Receptor 
AHI        : Apnoea/ Hypopnea Index 
BMI       : Body Mass Indes 
DAP: Diastolic Arterial Pressure 
DBP: Diastolic Blood Pressure 
EH : Essential Hypertension 
GAS       :Genetic Association Studies 
MABP   : Mean Arterial Blood Pressure 
OSA: Obstructive Sleep Apnoea 
SAP: Systolic Arterial Pressure 
SBP: Systolic Blood Pressure 
SNP      : Single Nucleotide Polymorphism 
STREGA: STrengthening the REporting of Genetic Association Studies 
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